http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Peter G Walley,Graham R Teakle,Jonathan D Moore,Charlotte J Allender,Vicky Buchanan-Wollaston,David AC Pink,Guy C Barker 한국식물생명공학회 2012 식물생명공학회지 Vol.39 No.1
The vegetable brassicas are an important crop worldwide and are of significant commercial value. In order to ensure our targets for food security are met it is important that these crops are continually improved to increase sustainability of production, increase nutritional quality and reduce waste. Development of resistances against both biotic and abiotic stress are recognised as being key. Plant breeding plays a vital role in addressing these issues through the development of new and improved varieties. This continued improvement is becoming evermore dependent on our ability to identify and introgress beneficial alleles from ‘exotic’ germplasm into elite breeding material. Increasingly, more diverse germplasm such as those found in genebanks is being screened for benificial allelic variation, however, plant breeders often find it difficult to make use of such material due to the time required to remove undesirable characteristics from progeny due to linkage drag. This article describes how we have attempted to overcome this and develop resources that make the diversity available within the Brassica oleracea genepool more accessible.
Walley, Peter G.,Teakle, Graham R.,Moore, Jonathan D.,Allender, Charlotte J.,Pink, David A.C.,Buchanan-Wollaston, Vicky,Barker, Guy C. The Korean Society of Plant Biotechnology 2012 식물생명공학회지 Vol.39 No.1
The vegetable brassicas are an important crop worldwide and are of significant commercial value. In order to ensure our targets for food security are met it is important that these crops are continually improved to increase sustainability of production, increase nutritional quality and reduce waste. Development of resistances against both biotic and abiotic stress are recognised as being key. Plant breeding plays a vital role in addressing these issues through the development of new and improved varieties. This continued improvement is becoming evermore dependent on our ability to identify and introgress beneficial alleles from 'exotic' germplasm into elite breeding material. Increasingly, more diverse germplasm such as those found in genebanks is being screened for benificial allelic variation, however, plant breeders often find it difficult to make use of such material due to the time required to remove undesirable characteristics from progeny due to linkage drag. This article describes how we have attempted to overcome this and develop resources that make the diversity available within the $Brassica$ $oleracea$ genepool more accessible.
박해심,이상학,이숙영,김미경,이병재,Viktoria Werkström,Peter Barker,James G. Zangrilli 대한천식알레르기학회 2019 Allergy, Asthma & Immunology Research Vol.11 No.4
Purpose: In the Phase III SIROCCO trial (NCT01928771), benralizumab significantly reduced asthma exacerbations and improved lung function and symptoms for patients with severe, uncontrolled eosinophilic asthma. The aim of this subgroup analysis was to evaluate efficacy and safety of benralizumab for Korean patients in SIROCCO. Methods: SIROCCO was a randomized, double-blind, parallel-group, placebo-controlled trial of 1,204 patients aged 12–75 years with severe asthma uncontrolled by high-dosage inhaled corticosteroids/long-acting β2-agonists (ICS/LABA). Patients received benralizumab 30 mg every 4 weeks (Q4W) or every 8 weeks (Q8W; first 3 doses Q4W) or placebo Q4W for 48 weeks. The primary analysis population comprised patients with blood eosinophil counts ≥ 300 cells/μL. This subgroup analysis evaluated Korean patients from this group. Results: Of 122 Korean patients randomized, 86 had blood eosinophil counts ≥ 300 cells/μL. Benralizumab reduced the annual asthma exacerbation rate by 70% (Q4W: rate estimate 0.79, rate ratio 0.30 [95% confidence interval {CI}, 0.13–0.65], nominal P = 0.003; n = 28) and 85% (Q8W: rate estimate 0.40, rate ratio 0.15 [95% CI, 0.06–0.36], nominal P < 0.001; n = 30) vs. placebo (rate estimate 2.67, n = 28). Prebronchodilator forced expiratory volume in 1 second was increased with benralizumab treatment by 0.270 L (Q4W: 95% CI, 0.039–0.500, nominal P = 0.023; n = 28) and 0.362 L (Q8W: 95% CI, 0.143–0.582, nominal P = 0.002; n = 30) vs. placebo (n = 27). Total asthma symptom score was similar for patients receiving either benralizumab Q4W (−0.27 [95% CI, −0.83 to 0.30], nominal P = 0.356; n = 27) or benralizumab Q8W (0.10 [95% CI, −0.44 to 0.65], nominal P = 0.708; n = 30) vs. placebo (n = 28). Drug-related adverse events were experienced by 2%, 8%, and 5% of patients in the placebo, benralizumab Q4W, and benralizumab Q8W arms. Conclusions: Benralizumab reduced annual asthma exacerbation rates, increased lung function, and was well-tolerated by Korean patients with severe, uncontrolled eosinophilic asthma.